Renaissance Technologies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Renaissance Technologies’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Buy	643,268 +366,496	+132%	+$6.64M	0.02%	928
2026 Q1	$5.16M	Buy	276,772 +142,300	+106%	+$2.36M	0.01%	1365
2025 Q4	$1.77M	Buy	+134,472	New	+$1.59M	﹤0.01%	1938
2023 Q4	–	Sell	-13,396	Closed	-$764K	–	3976
2023 Q3	$764K	Sell	13,396 -2,104	-14%	-$116K	﹤0.01%	2477
2023 Q2	$791K	Sell	15,500 -7,200	-32%	-$194K	﹤0.01%	2611
2023 Q1	$486K	Buy	22,700 +11,091	+96%	+$186K	﹤0.01%	2905
2022 Q4	$122K	Buy	+11,609	New	+$103K	﹤0.01%	3561

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies's MLTX Position: Q2 2026 in Review

Renaissance Technologies increased its MoonLake Immunotherapeutics (MLTX) stake by 132% in Q2 2026, buying an estimated $6.64M and bringing the position to 643,268 shares worth $12.5M. The position accounts for 0.02% of the portfolio, ranked #928.

Renaissance Technologies first reported a position in MLTX in Q4 2022 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Renaissance Technologies held 643,268 shares of MoonLake Immunotherapeutics worth $12.5M as of Q2 2026.
Renaissance Technologies bought 366,496 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $6.64M.
MoonLake Immunotherapeutics made up 0.02% of Renaissance Technologies's portfolio in Q2 2026, its #928 holding.
Renaissance Technologies first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 7 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.